Longevity as an Asset Class: The $800B Opportunity
As global life expectancy gaps narrow and bio-tech advances accelerate, longevity is transforming from a lifestyle trend into a legitimate asset class.
VCs are placing billion-dollar bets. ARCH Venture Partners, Andreessen Horowitz and Google's AI fund are circling the NAD+ and senolytic spaces.
The thesis: extending healthspan isn't just humanitarian—it's economically rational. A 10-year delay in age-related disease could unlock $2.8T in productivity gains.
Will this be the next software? Or will regulatory hurdles and hype cycles slow the momentum?
— Apple Lau, Contributing Editor